Patrizia Banfi

1.3k total citations
18 papers, 225 citations indexed

About

Patrizia Banfi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Patrizia Banfi has authored 18 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Patrizia Banfi's work include Protein Kinase Regulation and GTPase Signaling (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Metal complexes synthesis and properties (3 papers). Patrizia Banfi is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Metal complexes synthesis and properties (3 papers). Patrizia Banfi collaborates with scholars based in Italy, United States and Sweden. Patrizia Banfi's co-authors include Romolo A. Gambetta, Cinzia Lanzi, Arturo Galvani, Franco Zunino, Elena Ardini, Maria Beatrice Saccardo, Manuela Gariboldi, Joseph G. Naglich, Tommaso A. Dragani and R. M. Borzilleri and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and International Journal of Cancer.

In The Last Decade

Patrizia Banfi

18 papers receiving 222 citations

Peers

Countries citing papers authored by Patrizia Banfi

Since Specialization

Citations

This map shows the geographic impact of Patrizia Banfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrizia Banfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrizia Banfi more than expected).

Fields of papers citing papers by Patrizia Banfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrizia Banfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrizia Banfi. The network helps show where Patrizia Banfi may publish in the future.

Co-authorship network of co-authors of Patrizia Banfi

This figure shows the co-authorship network connecting the top 25 collaborators of Patrizia Banfi. A scholar is included among the top collaborators of Patrizia Banfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrizia Banfi. Patrizia Banfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models 2023 ·Cancer Research ·Claudia Perrera, Maurizio Pulici, Patrizia Banfi, Nilla Avanzi, Davide Carenzi, Daniele Casero, Antonella Ciavolella, Laura Gianellini, Fabio Gasparri, Grazia Saturno, Barbara Valsasina, Elena Ardini, Alessia Montagnoli, Arturo Galvani, Antonella Isacchi	3
2	Abstract 4785: NMS-E668, a highly potent orally available RET inhibitor with selectivity towards VEGFR2 and demonstrated antitumor efficacy in multiple RET-driven cancer models 2018 ·Cancer Research ·Elena Ardini, Patrizia Banfi, Nilla Avanzi, Marina Ciomei, Paolo Polucci, Alessandra Cirla, (unknown), Andrea Borgia, (unknown), Cinzia Cristiani, Dario Ballinari, Eduard Felder, Daniele Donati, Arturo Galvani, Antonella Isacchi, Maria Menichincheri	2
3	Mcl-1 antagonism is a potential therapeutic strategy in a subset of solid cancers 2014 ·Experimental Cell Research ·(unknown), Patrizia Banfi, Fabio Gasparri, R. M. Borzilleri, Percy Carter, Lyndon A. M. Cornelius, Marco M. Gottardis, (unknown), Claudio Mapelli, Joseph G. Naglich, Andrew J. Tebben, Gregory D. Vite, Wilma Pastori, Clara Albanese, Emiliana Corti, Dario Ballinari, Arturo Galvani	27
4	310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101 2014 ·European Journal of Cancer ·Daniel J. Anderson, Marina Ciomei, Patrizia Banfi, (unknown), Elena Ardini, Arturo Galvani, (unknown)	10
5	Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models . 2013 ·Cancer Research ·Elena Ardini, Maria Menichincheri, Patrizia Banfi, Daniele Casero, Maria Laura Giorgini, Maria Beatrice Saccardo, Nadia Amboldi, Nilla Avanzi, Paolo Orsini, Antonella Isacchi, Enrico Pesenti, Arturo Galvani	9
6	Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·Heidi L. Perez, Patrizia Banfi, J. A. Bertrand, (unknown), (unknown), Kyoung Kim, Jonathan Lippy, (unknown), Joseph G. Naglich, Robert J. Schmidt, Andrew J. Tebben, Paola Vianello, Donna Wei, Liping Zhang, Arturo Galvani, Louis J. Lombardo, R. M. Borzilleri	29
7	Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·Gretchen M. Schroeder, Donna Wei, Patrizia Banfi, Zhen‐Wei Cai, Jonathan Lippy, Maria Menichincheri, (unknown), Joseph G. Naglich, Becky Penhallow, Heidi L. Perez, John S. Sack, Robert J. Schmidt, Andrew J. Tebben, Chunhong Yan, Liping Zhang, Arturo Galvani, Louis J. Lombardo, R. M. Borzilleri	18
8	In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. 2011 ·Elena Ardini, Maria Menichincheri, Patrizia Banfi, Maria Beatrice Saccardo, Luisa Rusconi, Nilla Avanzi, Nadia Amboldi, Daniele Casero, (unknown), Antonella Isacchi, Daniele Donati, Enrico Pesenti, Arturo Galvani	9
9	Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. 2011 ·Molecular Cancer Therapeutics ·Elena Ardini, Maria Menichincheri, Patrizia Banfi, Maria Beatrice Saccardo, Luisa Rusconi, Nilla Avanzi, Nadia Amboldi, Daniele Casero, (unknown), Antonella Isacchi, Daniele Donati, Enrico Pesenti, Arturo Galvani	17
10	Structure-based optimization of potent PDK1 inhibitors 2010 ·Bioorganic & Medicinal Chemistry Letters ·Mauro Angiolini, Patrizia Banfi, Elena Casale, Francesco Casuscelli, Claudio Fiorelli, Maria Beatrice Saccardo, (unknown), Fabio Zuccotto	18
11	Synthesis of Alkyl Chain-Modified Ether Lipids and Evaluation of Their in Vitro Cytotoxicity 1995 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Patrizia Banfi, Romolo A. Gambetta, Franco Zunino, David Mauleón, Germano Carganico	5
12	The daunorubicin-binding protein of Mr 54,000 is an aldehyde dehydrogenase and is down-regulated in mouse liver tumors and in tumor cell lines. 1994 ·Molecular Pharmacology ·Patrizia Banfi, Cinzia Lanzi, Felicia Stefania Falvella, Manuela Gariboldi, Romolo A. Gambetta, Tommaso A. Dragani	23
13	Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes 1994 ·International Journal of Cancer ·(unknown), Patrizia Banfi, Elena Sala, Marialuisa Sensi, Rosanna Supino, Franco Zunino, Romolo A. Gambetta	22
14	Lipid peroxidation, phosphoinositide turnover and protein kinase C activation in human platelets treated with anthracyclines and their complexes with Fe(III) 1992 ·Biochemical Pharmacology ·Patrizia Banfi, Ornella Parolini, Cinzia Lanzi, Romolo A. Gambetta	6
15	Modulation of epidermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor 1991 ·Cancer Letters ·(unknown), Paola Perego, Patrizia Banfi, F. Zunino	2
16	Protein kinase C activation by anthracyclines in swiss 3T3 cells 1991 ·International Journal of Cancer ·Cinzia Lanzi, Romolo A. Gambetta, Paola Perego, Patrizia Banfi, (unknown), (unknown), Franco Zunino	11
17	Protein Kinase C Activation and Lipid Peroxidation by Doxorubicin Analogues 1989 ·Tumori Journal ·Romolo A. Gambetta, Patrizia Banfi, Cinzia Lanzi, (unknown), Franco Zunino	5
18	Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets 1988 ·Biochemical Pharmacology ·Cinzia Lanzi, Patrizia Banfi, Fernando Ravagnani, Romolo A. Gambetta	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact